Literature DB >> 2580038

Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity.

A D Hess, L Horwitz, W E Beschorner, G W Santos.   

Abstract

Lethally irradiated rats reconstituted with syngeneic bone marrow and treated with cyclosporine (CsA) for 40 d develop a graft-vs.-host disease-like syndrome (GVHD) after CsA therapy. We attempted to assess the development of autoreactivity in these animals. Results revealed that a majority of the animals with syngeneic GVHD develop autocytotoxic T lymphocytes of the OX8 phenotype. In addition to reactivity with self, these cells were capable of lysing appropriate target cells from a variety of different rat strains. The target antigens appeared to be class II major histocompatibility antigens, because lysis could be effectively blocked by an anti-Ia monoclonal antibody. Cold target inhibition studies indicated that one effector cell was capable of lysing various target cells, and provided evidence against a polyclonal activation of multiple anti-Ia-reactive cells. These results suggested that the anti-class II autoreactive cell associated with syngeneic GVHD either recognizes a common class II determinant ("public" epitope) shared by multiple strains of rats, or was polyspecific with respect to "private" class II determinants.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580038      PMCID: PMC2189060          DOI: 10.1084/jem.161.4.718

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Mode of action of cyclosporin A: a new immunosuppressive agent.

Authors:  D J White; R Y Calne; A Plumb
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

2.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

3.  Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity.

Authors:  J F Borel
Journal:  Immunology       Date:  1976-10       Impact factor: 7.397

4.  Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR.

Authors:  A D Hess; P J Tutschka
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

5.  Effect of cyclosporin A on human lymphocyte responses in vitro. II. Induction of specific alloantigen unresponsiveness mediated by a nylon wool adherent suppressor cell.

Authors:  A D Hess; P J Tutschka; G W Santos
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

6.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

7.  Macrophages suppress CTL generation in rat mixed leukocyte cultures.

Authors:  A Weiss; F W Fitch
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

8.  Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A.

Authors:  R Y Calne; D J White; K Rolles; D P Smith; B M Herbertson
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

9.  Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment.

Authors:  C J Green; A C Allison
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

10.  Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution.

Authors:  A Glazier; P J Tutschka; E R Farmer; G W Santos
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  30 in total

1.  Effects of cyclosporin A on T-cell development in organ-cultured foetal thymus.

Authors:  Y Takeuchi; T Horiuchi; T Sugimoto; H Matsuda; H Yagita; K Okumura
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

2.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

3.  Patterns of MHC antigenic modulation in cyclosporine-induced autoimmunity. Implications for pathogenesis.

Authors:  N A Parfrey; G J Prud'homme
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

Review 4.  Immunomodulation following chemotherapy.

Authors:  M Obadina; U Verma; M Hawkins; A Mazumder
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 5.  Autologous graft-versus-host disease.

Authors:  M J Kennedy; A D Hess
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

6.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

7.  Immunosuppression with cyclosporin A alters the thymic microenvironment.

Authors:  M Kanariou; R Huby; H Ladyman; M Colic; G Sivolapenko; I Lampert; M Ritter
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

8.  Induction of self-reactive T cells after murine coronavirus infection.

Authors:  S Kyuwa; K Yamaguchi; Y Toyoda; K Fujiwara
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

Review 9.  Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation.

Authors:  M J Kennedy; R J Jones
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 10.  Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach.

Authors:  Robert Frank Cornell; Parameswaran Hari; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-29       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.